Telomir Pharmaceuticals, Inc.’s Lock-Up Period To Expire on August 7th (NASDAQ:TELO)

Telomir Pharmaceuticals’ (NASDAQ:TELO) lock-up period is set to end on Wednesday, August 7th. Telomir Pharmaceuticals had issued 1,000,000 shares in its initial public offering on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Telomir Pharmaceuticals Trading Down 3.6 %

TELO stock opened at $3.34 on Friday. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $20.72. The firm has a fifty day moving average price of $4.69.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.23) earnings per share for the quarter.

Institutional Investors Weigh In On Telomir Pharmaceuticals

An institutional investor recently bought a new position in Telomir Pharmaceuticals stock. Suncoast Equity Management purchased a new stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 24,391 shares of the company’s stock, valued at approximately $126,000. Suncoast Equity Management owned approximately 0.08% of Telomir Pharmaceuticals at the end of the most recent quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.